Controversy Over New Breast Cancer Screening Guidelines

The news caused shock and anger nationwide:  The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.  The new guidelines are intended to reduce the unnecessary treatment and...

Spherix Shares Rise on Promising Diabetes Drug Data

Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate. Patients in the NEET (Naturlose Efficacy Evaluation Trial) study experienced a significant drop in blood glucose after taking D-tagatose. Drops in body mass...

Burrill Report: Biotech Innovation Gets the Cash

By Marie Daghlian, The Burrill Report If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation. On the receiving end this week, Alder Biopharmaceuticals stands to reap more than $1 billion from collaboration with Bristol-Myers Squibb for the development and...

Adeona’s Experimental RA Drug Does Well in Phase II Trial

Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate. The study found that oral dnaJP1 used in conjunction with the commercially approved RA medication hydroxychloroquine was more effective...

NicOx Reports Positive Data for Cholesterol Drug

NicOx announced that NCX 6560, its drug candidate for high cholesterol, met its primary and secondary endpoints in a Phase Ib man-in study.  The drug demonstrated top-line safety and tolerability, along with cholesterol-lowering effects, at all tested doses.  NCX 6560 was tested against a placebo and...

Ironwood Receives $75M from Astellas for IBS Drug

While it may not be fatal, irritable bowel syndrome (IBS) ranks high in discomfort and embarrassment.  The chronic gastrointestinal disorder is characterized by symptoms such as cramping, bloating, constipation, gas, and diarrhea.  There is no cure for IBS.  Its cause isn’t even certain. ...

Avanir Shares Rise on Zenvia Trial Data

Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis (MS) drug Zenvia met its goal in a six-month clinical trial.  The data showed that the low-dose version of Zenvia significantly reduced the number and severity of...

ProtoxPresents Data, Awaits Key Results for PRX302

By Mike Havrx ProActive Newsroom Protox Therapeutics (TSX: PRX.TO) (OTC: PTXRF.PK) applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. The Company’s clinical-stage pipeline is based on the PORxin and INxin...